Novel approaches to new therapies for hepatitis B virus infection

Rohit Loomba, T. Jake Liang

Research output: Contribution to journalArticle

Abstract

Hepatitis B is one of the most prevalent viral diseases in the world. It leads to chronic liver disease in 10% of infected individuals, putting them at an increased risk for liver-related morbidity and mortality from complications of cirrhosis and hepatocellular carcinoma. Despite the success of universal hepatitis B vaccination in many countries, this disease remains a major public health problem, resulting in more than 500,000 deaths per year. Although the current therapy for chronic hepatitis B (CHB) is effective, it is not optimal; novel approaches to the management of CHB are needed. An improved understanding of virus-host interactions, advances in gene therapy, the development of molecular therapies targeted at different stages of the hepatitis B virus life cycle, and new insights into various approaches of immune modulation will lead to the development of better therapeutic agents for the management of CHB. These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalAntiviral Therapy
Volume11
Issue number1
StatePublished - 2006
Externally publishedYes

Fingerprint

Virus Diseases
Hepatitis B virus
Chronic Hepatitis B
Hepatitis B
Molecular Targeted Therapy
Therapeutics
Life Cycle Stages
Genetic Therapy
Liver Diseases
Hepatocellular Carcinoma
Vaccination
Fibrosis
Chronic Disease
Public Health
Viruses
Morbidity
Mortality
Liver

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel approaches to new therapies for hepatitis B virus infection. / Loomba, Rohit; Liang, T. Jake.

In: Antiviral Therapy, Vol. 11, No. 1, 2006, p. 1-15.

Research output: Contribution to journalArticle

Loomba, R & Liang, TJ 2006, 'Novel approaches to new therapies for hepatitis B virus infection', Antiviral Therapy, vol. 11, no. 1, pp. 1-15.
Loomba, Rohit ; Liang, T. Jake. / Novel approaches to new therapies for hepatitis B virus infection. In: Antiviral Therapy. 2006 ; Vol. 11, No. 1. pp. 1-15.
@article{9dec77528e5a4980a5bec41a82ffafd5,
title = "Novel approaches to new therapies for hepatitis B virus infection",
abstract = "Hepatitis B is one of the most prevalent viral diseases in the world. It leads to chronic liver disease in 10{\%} of infected individuals, putting them at an increased risk for liver-related morbidity and mortality from complications of cirrhosis and hepatocellular carcinoma. Despite the success of universal hepatitis B vaccination in many countries, this disease remains a major public health problem, resulting in more than 500,000 deaths per year. Although the current therapy for chronic hepatitis B (CHB) is effective, it is not optimal; novel approaches to the management of CHB are needed. An improved understanding of virus-host interactions, advances in gene therapy, the development of molecular therapies targeted at different stages of the hepatitis B virus life cycle, and new insights into various approaches of immune modulation will lead to the development of better therapeutic agents for the management of CHB. These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies.",
author = "Rohit Loomba and Liang, {T. Jake}",
year = "2006",
language = "English (US)",
volume = "11",
pages = "1--15",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

TY - JOUR

T1 - Novel approaches to new therapies for hepatitis B virus infection

AU - Loomba, Rohit

AU - Liang, T. Jake

PY - 2006

Y1 - 2006

N2 - Hepatitis B is one of the most prevalent viral diseases in the world. It leads to chronic liver disease in 10% of infected individuals, putting them at an increased risk for liver-related morbidity and mortality from complications of cirrhosis and hepatocellular carcinoma. Despite the success of universal hepatitis B vaccination in many countries, this disease remains a major public health problem, resulting in more than 500,000 deaths per year. Although the current therapy for chronic hepatitis B (CHB) is effective, it is not optimal; novel approaches to the management of CHB are needed. An improved understanding of virus-host interactions, advances in gene therapy, the development of molecular therapies targeted at different stages of the hepatitis B virus life cycle, and new insights into various approaches of immune modulation will lead to the development of better therapeutic agents for the management of CHB. These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies.

AB - Hepatitis B is one of the most prevalent viral diseases in the world. It leads to chronic liver disease in 10% of infected individuals, putting them at an increased risk for liver-related morbidity and mortality from complications of cirrhosis and hepatocellular carcinoma. Despite the success of universal hepatitis B vaccination in many countries, this disease remains a major public health problem, resulting in more than 500,000 deaths per year. Although the current therapy for chronic hepatitis B (CHB) is effective, it is not optimal; novel approaches to the management of CHB are needed. An improved understanding of virus-host interactions, advances in gene therapy, the development of molecular therapies targeted at different stages of the hepatitis B virus life cycle, and new insights into various approaches of immune modulation will lead to the development of better therapeutic agents for the management of CHB. These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=33644537402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644537402&partnerID=8YFLogxK

M3 - Article

C2 - 16518955

AN - SCOPUS:33644537402

VL - 11

SP - 1

EP - 15

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -